

MAP Pharmaceuticals, Inc.  
Form 8-K  
August 02, 2011

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): August 2, 2011**

**MAP PHARMACEUTICALS, INC.**

**(Exact Name of Registrant as Specified in its Charter)**

**Delaware**  
**(State or Other Jurisdiction**  
  
**of Incorporation)**

**001-33719**  
**(Commission**  
  
**File Number)**

**20-0507047**  
**(IRS Employer**  
  
**Identification No.)**

Edgar Filing: MAP Pharmaceuticals, Inc. - Form 8-K

2400 Bayshore Parkway, Suite 200, Mountain

View, CA

(Address of Principal Executive Offices)

Registrant's telephone number, including area code: (650) 386-3100

94043

(Zip Code)

(Former Name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( *see* General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events**

On August 2, 2011, MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) (the Company ) announced that the Company s New Drug Application ( NDA ) for LEVADEX® orally inhaled migraine drug for the potential acute treatment of migraine in adults has been accepted for filing by the U.S. Food and Drug Administration. The Company also announced that the acceptance for filing of the LEVADEX NDA triggers a milestone payment to the Company by Allergan, Inc. pursuant to the terms of the Collaboration Agreement between the Company, Allergan, Inc. and Allergan Sales LLC dated January 28, 2011.

The Company announced the acceptance for filing of the NDA in a press release that is attached hereto as Exhibit 99.1

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

**Exhibit**

<b>No.</b>	<b>Description</b>
99.1	Press Release dated August 2, 2011

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 2, 2011

**MAP PHARMACEUTICALS, INC.**

By: /s/ Charlene A. Friedman

Name: Charlene A. Friedman

Title: Senior Vice President, General Counsel and Secretary

**INDEX TO EXHIBITS FILED WITH  
THE CURRENT REPORT ON FORM 8-K DATED AUGUST 2, 2011**

**Exhibit**

<b>No.</b>	<b>Description</b>
99.1	Press Release dated August 2, 2011